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GM1-gangliosidosis is a rare lysosomal storage disorder char-
acterized clinically by a wide range of variable neurovisceral,
ophthalmological and dysmorphic features. Without enough
functional β-galactosidase, GM1-gangliosides cannot be de-
graded in lysosomes, and accumulate to toxic levels in many
tissues and organs, particularly in the brain. In spite of several
approaches for the treatment of GM1-gangliosidosis, such as
enzyme replacement therapy, gene therapy, chemical chaper-
one therapy, there is no treatment available for patients with
ganglioside storage diseases. Therefore, development of novel
drugs for GM1-gangliosidosis is needed.
Cyclodextrins (CyDs) are cyclic oligosaccharides that are
widely used in the pharmaceutical field. CyDs can extract cell
membrane components such as cholesterol and phospholip-
ids from lipid rafts, which contain high concentrations of
cholesterol and glycosphingolipids including GM1-gangliosides.
Meanwhile, the systemic administration of 2-hydroxypropyl-
β-CyD (HP-β-CyD) to mice lacking Niemann–Pick disease type
C (NPC) protein was beneficial probably due to the ability to
modify the internal environment of the endosomal/lysosomal
compartment.Thus, we hypothesized that CyDs are useful for
treatment of GM1-gangliosidosis.Therefore, in the present study,
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we investigated the effects of various CyDs on the GM1-
ganglioside level accumulated in EA1 cells, fibroblasts from
patients with GM1-gangliosidosis [1].
We examined the effects of CyDs on the GM1-ganglioside
levels in EA1 cells using FITC-labeled cholera toxin B-subunit,
which can bind to GM1-gangliosides specifically. Herein,we used
the two experimental conditions, i.e. (1) 10 mM CyD and 1 h
treatment and (2) 1 mM CyD and 24 h treatment. In our pre-
liminary study, under the former conditions, we confirmed that
CyDs extracted membrane components from the EA1 cells.
Under the latter conditions, we revealed that CyDs except for
M-β-CyD did not extract the membrane components.The treat-
ment with 10 mM CyDs for 1 h did not significantly change
fluorescence intensity derived from FITC. Meanwhile, the treat-
ment with 1 mM CyDs for 24 h decreased the fluorescent
intensity, especially the prominent lowering effects of methyl-
β-CyD and dimethyl-α-CyD were shown with statistical
difference, compared to those of the other CyDs. The similar
lowering effects of CyDs on the fluorescence intensity derived
from Alexa®488-conjugated CTB (Alexa-CTB) were observed in
EA1 cells using a confocal laser scanning microscopy. Hence,
the lowering effect of CyDs on the GM1-ganglioside levels in
the cells was highly unlikely to be associated with the extract-
ing ability of CyDs on plasma membrane components of the
cells. Collectively, these results suggest that CyDs impair the
GM1-ganglioside levels in EA1 cells in a different way from
the extraction ability of CyDs on membrane components.
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